The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer

Genetics in Medicine

Volumn 12, Issue 2, 2010, Pages 93-104

  Mvundura, Mercy ^a   Grosse, Scott D ^b,e   Hampel, Heather ^c   Palomaki, Glenn E ^d  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^b NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^d BROWN UNIVERSITY   (United States)

^e NONE   (United States)

Author keywords

Cancer; Cost effectiveness analysis; Economic evaluation; Genetic testing; Genomics; HNPCC; Lynch syndrome

Indexed keywords

ADULT; ARTICLE; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; FAMILIAL CANCER; GENE SEQUENCE; GENETIC ANALYSIS; HEALTH CARE SYSTEM; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; PREVENTIVE HEALTH SERVICE;

COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; COST-BENEFIT ANALYSIS; FEMALE; GENETIC TESTING; HUMANS; MALE;

EID: 77149122082     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181cd666c     Document Type: Article

References (51)

1. Bonis PA, Trikalinos TA, Chung M, et al. Hereditary nonpolyposis colo-rectal cancer: diagnostic strategies and their implications. Evid Rep Technol Assess (Full Rep) 2007;150:1-180.
2. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 2009;11:1-22.
3. Recommendations from the EGAPP Working Group. Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009;11:35-41.
4. Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpol-yposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998;338:1481-1487.
5. Pinol V, Castells A, Andreu M, et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 2005;293:1986-1994.
6. Samowitz WS, Curtin K, Lin HH, et al. The colon cancer burden of genetically defined hereditary nonpolyposis colon cancer. Gastroenterology 2001;121:830-838.
7. Vasen HF, Möslein G, Alonso A, et al. Recommendations to improve identification of hereditary and familial colorectal cancer in Europe [published online ahead of print September 18, 2009]. Fam Cancer doi:10.1007/s10689-009- 9291-3.
8. Cancer Facts and Figures 2008. Available at: http://www.cancer.org/ downloads/STT/2008CAFFfinalsecured.pdf. Accessed December 31, 2008.
9. US Cancer Statistics Working Group. United States cancer statistics: 1999-2005 incidence and mortality web-based report. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, 2009. Available at: www.cdc.gov/uscs. Accessed February 19, 2009.
10. de la Chapelle A, Palomaki G, Hampel H. Identifying Lynch syndrome. Int J Cancer 2009;125:1492-1493.
11. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005;352:1851-1860.
12. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008;26: 5783-5788.
13. van Gils P, van den Berg M, van Kranen H, de Wit AG. A literature review of assumptions on test characteristics and adherence in economic evaluations of colonoscopy and CT-colonography screening. Eur J Cancer 2009;45: 1554-1559.
14. Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the US Preventive Services Task Force. Ann Intern Med 2002;137:96-104. (Pubitemid 34779153)
15. Hassan C, Zullo A, Winn S, Morini S. Cost-effectiveness of capsule endos-copy in screening for colorectal cancer. Endoscopy 2008;40:414-421.
16. Sonnenberg A, Delco F, Inadomi JM. Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med 2000;133:573-584. (Pubitemid 30778444)
17. Ramsey SD, Clarke L, Etzioni R, Higashi M, Berry K, Urban N. Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med 2001;135:577-588.
18. Ramsey SD, Burke W, Clarke L. An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer. Genet Med 2003;5:353-363.
19. Olsen KR, Bojesen SE, Gerdes AM, Lindorff-Larsen K, Bernstein IT. Cost-effectiveness of surveillance programs for families at high and moderate risk of hereditary non-polyposis colorectal cancer. Int J Technol Assess Health Care 2007;23:89-95.
20. Hagen A, Hessabi HK, Gorenoi V, Schonermark MP. [Cost-effectiveness evaluation of predictive molecular diagnostics using the example of hereditary non-polyposis colorectal cancer (HNPCC).] Gesundheitswesen 2008; 70:18-27.
21. Kievit W, de Bruin JH, Adang EM, et al. Cost effectiveness of a new strategy to identify HNPCC patients. Gut 2005;54:97-102.
22. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
23. Chapman RH, Berger M, Weinstein MC, Weeks JC, Goldie S, Neumann PJ. When does quality-adjusting life-years matter in cost-effectiveness analysis? Health Econ 2004;13:429-436.
24. Tengs TO. Cost-effectiveness versus cost-utility analysis of interventions for cancer: does adjusting for health-related quality of life really matter? Value Health 2004;7:70-78.
25. Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 2006;26:410-420
26. Ramsey SD, Andersen MR, Etzioni R, et al. Quality of life in survivors of colorectal carcinoma. Cancer 2000;88:1294-1303.
27. Ramsey SD, Berry K, Moinpour C, Giedzinska A, Andersen MR. Quality of life in long term survivors of colorectal cancer. Am J Gastroenterol 2002; 97:1228-1234.
28. Ramsey S, Blough D, McDermott C, et al. Will knowledge of gene-based colorectal cancer disease risk influence quality of life and screening behavior? Public Health Genomics 2010;13:1-12.
29. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003;124:544-560.
30. Drummond M, Sculpher M. Common methodological flaws in economic evaluations. Med Care 2005;43:5-14.
31. Overbeek LI, Ligtenberg MJ, Willems RW, et al. Interpretation of immu-nohistochemistry for mismatch repair proteins is only reliable in a specialized setting. Am J Surg Pathol 2008;32:1246-1251.
32. Ries L, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2005. Bethesda, MD, National Cancer Institute. Available at: http:// seer.cancer.gov/csr/1975-2005/results-merged/sect-06-colon-rectum.pdf. Accessed May 5, 2008.
33. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609-618.
34. Stupart DA, Goldberg PA, Algar U, Ramesar R. Surveillance colonoscopy improves survival in a cohort of subjects with a single mismatch repair gene mutation. Colorectal Dis 2009;11:126-130.
35. Ramsey SD, Burke W, Pinsky L, Clarke L, Newcomb P, Khoury MJ. Family history assessment to detect increased risk for colorectal cancer: conceptual considerations and a preliminary economic analysis. Cancer Epidemiol Biomarkers Prev 2005;14:2494-2500.
36. Bessa X, Balleste B, Andreu M, et al. A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening. Clin Gastroenterol Hepatol 2008;6:206-214.
37. Maciosek MV, Edwards NM, Coffield AB, et al. Priorities among effective clinical preventive services: methods. Am J Prev Med 2006;31:90-96.
38. Grosse SD, Teutsch SM, Haddix AC. Lessons from cost-effectiveness research for United States public health policy. Annu Rev Public Health 2007;28:365-391.
39. Grosse SD. Assessing cost effectiveness in health care: the history of the $50,000 per QALY threshold. Exp Rev Pharmacoeconomics Outcome Res 2008;8:165-178.
40. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 2008;46:349-356.
41. Weinstein MC. How much are Americans willing to pay for a quality-adjusted life year? Med Care 2008;46:343-345.
42. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kaste-lein JJ. Review of first 5 years of screening for familial hypercholesterol-aemia in the Netherlands. Lancet 2001;357:165-168.
43. Schofield L, Watson N, Grieu F, et al. Population-based detection of Lynch syndrome in young colorectal cancer patients using microsatellite instability as the initial test. Int J Cancer 2009;124:1097-1102.
44. Wagner A, van Kessel I, Kriege MG, et al. Long term follow-up of HNPCC gene mutation carriers: compliance with screening and satisfaction with counseling and screening procedures. Fam Cancer 2005;4:295-300.
45. Järvinen HJ, Renkonen-Sinisalo L, Aktán-Collán K, Peltomäki P, Aaltonen LA, Mecklin JP. Ten years after mutation testing for Lynch Syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 2009;27:4793-4797.
46. Halbert CH, Lynch H, Lynch J, et al. Colon cancer screening practices following genetic testing for hereditary nonpolyposis colon cancer (HNPCC) mutations. Arch Intern Med 2004;164:1881-1887.
47. Kwon JS, Sun CC, Peterson SK, et al. Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome. Cancer 2008;113:326-335.
48. Stoffel E, Mukherjee B, Raymond VM, et al. Calculation of risk of colo-rectal and endometrial cancer among patients with Lynch syndrome. Gas-troenterology 2009;137:1621-1627.
49. Quehenberger F, Vasen HF, van Houwelingen HC. Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet 2005;42:491-496.
50. Barnetson RA, Tenesa A, Farrington SM, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 2006;354:2751-2763.
51. Watson P, Lin KM, Rodriguez-Bigas MA, et al. Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family members. Cancer 1998;83:259-266. (Pubitemid 28317805)